Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) announces it has entered into a definitive agreement to acquire Elektrofi, Inc. (“Elektrofi”), a biopharmaceutical company with a breakthrough ultra-high concentration microparticle technology for biologics, branded Hypercon™. The transaction, which is comprised of an upfront payment of $750 million and up to three $50 million milestone payments contingent on three separate product regulatory approvals, was unanimously approved by the Boards of Directors of both Halozyme and Elektrofi. The Hypercon™ technology is an innovative microparticle approach that sets a new standard in the pursuit of hyper concentration, enabling high protein concentrations while maintaining syringeability.
Read the full article: Halozyme to Acquire Elektrofi //
Source: https://www.prnewswire.com/news-releases/halozyme-to-acquire-elektrofi-expanding-our-offerings-in-innovative-drug-delivery-and-strengthening-long-term-growth-into-2040s-302571888.html